| [1] |
Siegel RL, Miller KD, Jemal A . Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7-30. DOI: 10.3322/caac.21442.
doi:10.3322/caac.21442 |
| [2] |
Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
doi:10.3322/caac.21338 |
| [3] |
Migali C, Milano M, Trapani D , et al. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond[J]. Ther Adv Med Oncol, 2016,8(5):360-374. DOI: 10.1177/1758834016658423.
doi:10.1177/1758834016658423 |
| [4] |
Keir ME, Butte MJ, Freeman GJ , et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008,26:677-704. DOI: 10.1146/annurev.immunol.26.021607.090331.
doi:10.1146/annurev.immunol.26.021607.090331 |
| [5] |
Hodi FS, Mihm MC, Soiffer RJ , et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients[J]. Proc Natl Acad Sci U S A, 2003,100(8):4712-4717. DOI: 10.1073/pnas.0830997100.
doi:10.1073/pnas.0830997100 |
| [6] |
Fehrenbacher L, Spira A, Ballinger M , et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLA R): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016,387(10030):1837-1846. DOI: 10.1016/S0140-6736(16)00587-0.
doi:10.1016/S0140-6736(16)00587-0 |
| [7] |
Champiat S, Lambotte O, Barreau E , et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559-574. DOI: 10.1093/annonc/mdv623.
doi:10.1093/annonc/mdv623 |
| [8] |
Eigentler TK, Hassel JC, Berking C , et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016,45:7-18. DOI: 10.1016/j.ctrv.2016.02.003.
doi:10.1016/j.ctrv.2016.02.003 |
| [9] |
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv119-iv142. DOI: 10.1093/annonc/mdx225.
doi:10.1093/annonc/mdx225 |
